International Kidney Cancer Symposium | Conference

Cytoreductive Nephrectomy Plus Active Surveillance Continues to Show Promise in mRCC
November 12, 2021

A select group of patients with metastatic renal cell carcinoma may benefit from cytoreductive nephrectomy followed by active surveillance as an alternative option to systemic therapy.

Proactive Approach for Managing Adverse Reactions Associated With Lenvatinib/Pembrolizumab Needed in Advanced RCC
November 05, 2021

As lenvatinib plus pembrolizumab combination therapy results in a wide range of adverse effects, some which even led to discontinuation of the treatment, investigators suggest a proactive strategy for patients with advanced renal cell carcinoma.

Cell Cycle Proliferation and Epithelial-Mesenchymal Transition Pathway Scores Predictive of Recurrence and Survival for ccRCC
November 05, 2021

Research from the 2021 International Kidney Cancer Symposium North America identified prognostic value in cell cycle proliferation and epithelial-mesenchymal transition pathway scores in clear cell renal cell carcinoma in predicting survival and recurrence.

Non-Clear Cell Renal Cell Carcinoma Strongly Associated With Proliferative Disease Subtypes
November 05, 2021

A notable association has been identified between non-clear cell renal cell carcinoma and proliferative disease.

David Braun, MD, PhD, on the Unique Experiences at IKCS
November 20, 2019

The next gen innovator discusses the integration of fields at the International Kidney Cancer Symposium in Miami.

Martin H. Voss, MD, on Bringing Different Disciplines Together at IKCS
November 20, 2019

The medical oncologist discusses the different talks that were presented at the International Kidney Cancer Symposium in Miami.

Lenvatinib, Pembrolizumab Combo Shows Promising Results in Metastatic RCC
November 05, 2019

Treatment with lenvatinib and pembrolizumab has shown promise in patients with metastatic clear cell renal cell carcinoma who have already received an immune checkpoint inhibitor.

Expert Discusses Service Focused on Immunotherapy-Related AEs
November 05, 2019

Massachusetts General Hospital’s Severe Immunotherapy Complications Service focuses on the increasing number of “rare” cases of immunotherapy-related adverse events.

Transplant Outcomes in Myeloma with Renal Insufficiency Improved
October 07, 2019

Autologous stem cell transplant has become safer over the years for patients with multiple myeloma and renal insufficiency.

Non-Aspirin NSAID Use Associated With Shorter Survival in Metastatic RCC
November 21, 2016

Metastatic renal cell carcinoma (mRCC) patients who use non-aspirin NSAIDs have poorer overall survival than aspirin users and NSAID non-users, according to a new pooled retrospective analysis.